Paraoxonase Activity and Expression Is Modulated by Therapeutics in Experimental Rat Nonalcoholic Fatty Liver Disease

Figure 2

Paraoxonase (PON) activity in sera (a) and livers (b); PON2 (c) and PON3 (d) mRNA expression in rat experimental fatty liver model. Fatty liver in Sprague-Dawley rats was induced by methionine-choline deficient diet (MCDD) for 9 weeks. Rats were treated for other 6 weeks with rosiglitazone (R); metformin (M); rosiglitazone + metformin combination (R+M); ezetimibe (E); valsartan (V); rosiglitazone + metformin + valsartan in combination (R+M+V) or rosiglitazone + metformin + valsartan + ezetimibe (R+M+V+E). “^#” indicates 𝑃<0.05 versus control group (fed by standard rat chow). “*” indicates 𝑃<0.05 versus MCDD group.

(a)

(b)

(c)

(d)